Brief: Myriad Genetics Launches Prolaris® + AI
26/05/2026 21:08
BRIEF-Myriad Genetics Launches Prolaris® + AI May 26 (Reuters) - Myriad Genetics Inc MYGN.O:
MYRIAD GENETICS LAUNCHES PROLARIS® + AI, THE FIRST PROSTATE CANCER TEST TO COMBINE GENOMICS AND DIGITAL PATHOLOGY ARTIFICIAL INTELLIGENCE (AI)
Source text: ID:nGNX8rPHQr
Further company coverage: MYGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Myriad Genetics
See all newsUS STOCKS ON THE MOVE-Hilton, MSCI, Tradeweb, Eli Lilly
US STOCKS ON THE MOVE-Hilton, MSCI, Tradeweb, Eli Lilly
Myriad jumps after agreeing to sell prenatal health testing business
Brief: Myriad Genetics To Sell Prenatal Health Testing Business To Labcorp
U.S. STOCKS ON THE MOVE- Medtronic, Comstock, Apple